Lebwohl David
SEC CIK 1810882 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NTLA | Intellia Therapeutics, Inc. | EVP, Chief Medical Off | 131.2K | — | $2.37M | 25 | 2021-08-09 | 2026-03-01 |
Most active insiders at NTLA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | LEONARD JOHN M | Pres, CEO, Dir | — | $1.44M |
| 2 | Cohen Fred E | Dir | $1.40M | — |
| 3 | Dulac Edward J III | EVP, CFO | — | $234.2K |
| 4 | BASTA JAMES | EVP, GC | — | $112.4K |
| 5 | Lebwohl David | EVP, Chief Medical Off | — | $109.6K |
| 6 | Dube Michael P | VP, CAO | — | $104.4K |
| 7 | Clark Eliana | EVP, Chief Technical Off | — | $96.0K |
| 8 | Schultes Birgit C | EVP, CSO | — | $78.9K |
| 9 | Bhanji Muna | Dir | — | — |
| 10 | Keresty Georgia | Dir | — | — |
Transactions 25
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-03 | 2026-03-01 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | A - Grant | $0.00 | +9,943 | 131.2K | +8% | $0 |
| 2026-01-07 | 2026-01-05 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | S - Sale | $9.21 | -11.9K | 121.2K | -9% | -$109.6K | |
| D | 2025-03-04 | 2025-03-01 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | A - Grant | $0.00 | +43.2K | 130.9K | +49% | $0 |
| 2025-01-07 | 2025-01-03 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | S - Sale | $12.18 | -9,557 | 87.7K | -10% | -$116.4K | |
| D | 2025-01-03 | 2025-01-01 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | M - OptEx | — | +3,189 | 97.2K | +3% | — |
| D | 2024-03-05 | 2024-03-01 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | A - Grant | $0.00 | +38.7K | 93.1K | +71% | $0 |
| 2024-01-05 | 2024-01-03 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | S - Sale | $29.46 | -5,843 | 54.4K | -10% | -$172.1K | |
| D | 2024-01-03 | 2024-01-01 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | M - OptEx | — | +3,187 | 60.2K | +6% | — |
| D | 2023-03-03 | 2023-03-01 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | A - Grant | $0.00 | +30.7K | 56.4K | +119% | $0 |
| 2023-01-06 | 2023-01-04 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | S - Sale | $37.21 | -2,574 | 25.7K | -9% | -$95.8K | |
| D | 2023-01-04 | 2023-01-01 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | M - OptEx | — | +3,187 | 28.3K | +13% | — |
| D | 2022-03-03 | 2022-03-01 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | A - Grant | $0.00 | +13.8K | 24.7K | +126% | $0 |
| D | 2022-03-03 | 2022-01-01 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | S - Sale+OE | $112.24 | -1,051 | 10.9K | -9% | -$118.0K |
| D | 2022-03-03 | 2022-01-01 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | M - OptEx | — | +3,187 | 12.0K | +36% | — |
| DM | 2021-11-09 | 2021-11-05 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | S - Sale+OE | $132.72 | -2,400 | 9,914 | -19% | -$318.5K |
| D | 2021-11-09 | 2021-11-05 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | M - OptEx | $12.62 | +2,400 | 11.1K | +28% | +$30.3K |
| DM | 2021-10-15 | 2021-10-14 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | S - Sale+OE | $128.44 | -2,400 | 9,714 | -20% | -$308.2K |
| D | 2021-10-15 | 2021-10-14 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | M - OptEx | $12.62 | +2,400 | 11.1K | +28% | +$30.3K |
| D | 2021-09-27 | 2021-09-24 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | M - OptEx | $12.62 | +7,923 | 8,714 | +1,002% | +$100.0K |
| D | 2021-09-23 | 2021-09-21 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | S - Sale+OE | $149.81 | -2,400 | 791 | -75% | -$359.5K |
| D | 2021-09-23 | 2021-09-21 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | M - OptEx | $12.62 | +2,400 | 3,191 | +303% | +$30.3K |
| D | 2021-09-01 | 2021-08-30 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | M - OptEx | $12.62 | +2,400 | 3,191 | +303% | +$30.3K |
| DM | 2021-09-01 | 2021-08-30 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | S - Sale+OE | $158.04 | -2,400 | 2,291 | -51% | -$379.3K |
| D | 2021-08-11 | 2021-08-09 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | M - OptEx | $12.62 | +2,400 | 3,191 | +303% | +$30.3K |
| D | 2021-08-11 | 2021-08-09 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Off | S - Sale+OE | $164.05 | -2,400 | 791 | -75% | -$393.7K |
Purchase Sale Sale after option exercise All abbreviations